



A Correlative Study of Estrogen Receptor Signaling: Molecular and Histological Perspectives in ER-Positive Breast Tumors

Sajjad Jawad Kadhim

Department of Biology, College of Education for Pure Sciences, University of Wasit, Iraq

Article Information

Received: 1-3-2026

Accepted: 16-3-2026

Published: 1-4-2026

Abstract

Breast tumor remains the most widespread and lethal malignancy affecting women worldwide. Approximately two-thirds of cases are classified as hormone receptor-positive, characterized by the expression of estrogen and progesterone receptors, and are closely regulated by estrogen signaling pathways. The primary therapeutic approach for these tumors involves antiestrogen agents; however, resistance to such treatments inevitably develops due to various molecular mechanisms. These include aberrant activation of the PI3K signaling cascade, mutations in the ESR1 gene, functional alterations of estrogen receptors, and disruptions in cell cycle regulation. In response to these challenges, novel therapeutic strategies have emerged, such as selective estrogen receptor degraders (SERDs) and combination regimens incorporating cyclin-dependent kinase (CDK) 4/6 inhibitors or PI3K pathway inhibitors. A comprehensive understanding of estrogen receptor biology is therefore essential for optimizing treatment outcomes and guiding the development of next-generation therapies. This study highlights current advances in the molecular mechanisms, signaling dynamics, and clinical implications of estrogen receptor activity in hormone-dependent breast cancer.

Keywords: *estrogen; endocrine resistance; breast tumor*

Introduction

In 2020, breast cancer was the most frequently diagnosed cancer globally, accounting for 11.7% of the 19.3 million new cases, slightly surpassing lung cancer at 11.4% . While lung cancer remains the leading cause of cancer-related deaths across all genders (18% of 10 million deaths), breast cancer is the most fatal malignancy among women, responsible for 15.5% of female cancer deaths and 6.9% of total cancer mortality . Although breast cancer predominantly affects women, approximately 1 in every 100 cases in

the United States occurs in men, who share similar pathological features. (Sung *et al.*, 2021)

Healthy mammary epithelium—whether ductal or lobular—consists of two main cell types: basal cells, which contribute to milk ejection through contractile activity, and luminal cells, which are responsible for milk production (Pandya & Moore, 2011). Luminal cells express cytokeratins 8 and 18, the epithelial adhesion molecule EpCam, and hormone receptors such as estrogen (ER), progesterone (PR), and prolactin receptors (Pellacani *et al.*, 2019). Basal cells, on the other hand, are characterized by the expression of cytokeratins 5, 14, and 17, as well as P-cadherin and desmosomal cadherins, along with markers associated with smooth muscle differentiation (Rodriguez-Boulan & Macara, 2014).

The development and differentiation of mammary epithelial cells are primarily regulated by estrogen, progesterone, and prolactin. Additionally, growth factors such as insulin-like growth factor (IGF), fibroblast growth factor (FGF), amphiregulin (AREG), and members of the epidermal growth factor (EGF) family play essential roles in mediating estrogen's effects during pubertal mammary gland development (Ciarloni *et al.*, 2007), (Troyer & Lee, 2001).

Breast cancer arises from the malignant transformation of ductal or lobular epithelial cells, resulting in a highly heterogeneous disease. This intratumoral heterogeneity enables cancer cells to dynamically reprogram their gene expression and behavior in response to microenvironmental cues, promoting tumor progression and resistance to therapy. Once locally advanced, the disease may metastasize to distant organs such as the brain, liver, lungs, or bones (Liang *et al.*, 2020).

Due to variations in anatomical origin, histological subtype, genetic profile, and hormonal dependency, breast tumors exhibit diverse levels of aggressiveness and clinical outcomes. These differences necessitate individualized therapeutic approaches (Harbeck *et al.*, 2019).

The estrogen receptor (ER) acts as a transcription factor that regulates genes involved in apoptosis, cell proliferation, and cell cycle progression. Upon activation, ER promotes the expression of oncogenic mediators such as MYC, Cyclin D1, FOXM1, GREB1, BCL2, amphiregulin, IGF-1, and CXCL12, which contribute to DNA damage and uncontrolled cell growth in response to estrogen signaling (Harbeck *et al.*, 2019).

When estrogen (E2) binds to ER, the receptor undergoes dimerization, translocates to the nucleus, adopts an active conformation, and recruits transcriptional coactivators. In contrast, antagonists like tamoxifen induce an inactive ER conformation that attracts corepressors, thereby inhibiting gene transcription (Shiau *et al.*, 1998).

Activated ER binds to estrogen-responsive elements (EREs) in the promoters of target genes. Additionally, ER can regulate genes lacking EREs by interacting with transcription factors such as AP1 and SP1 via serum-responsive elements (SREs) (Mal *et al.*, 2020), (Girault *et al.*, 2003). This genomic activity governs the transcription of hundreds of genes linked to cellular growth and differentiation. Most ER-positive (ER+) or luminal breast cancers arise from dysregulated ER expression, altered receptor activity, or disrupted function of ER-associated cofactors and target genes. (Le Romancer *et al.*, 2011).

Estrogens also activate other receptors, including ER β and GPER. ER β , encoded by the ESR2 gene, shares structural similarities with ER α and is expressed in both reproductive tissues (e.g., mammary glands, ovaries, uterus, testes) and non-reproductive organs (e.g., brain, lungs, adrenal glands, adipose tissue) (Acconcia *et al.*, 2005). ER β interacts with various transcriptional cofactors and shares ligands with ER α , including estrogens and selective estrogen receptor modulators (SERMs). Unlike ER α , ER β activation often leads to reduced proliferation and increased apoptosis, although these effects depend on tissue

context, cellular environment, and coexpression patterns (Barton et al., 2018).

While ER β expression is generally associated with favorable prognosis in breast cancer, some studies suggest a more complex role. Coactivators such as AIB1, NF- κ B, and TIF-2 have been shown to enhance ER α -driven tumor growth and metastasis (De Francesco et al., 2014).(Dustin et al., 2019).

High expression of these cofactors in aggressive tumor subtypes correlates with poor clinical outcomes, indicating that they may amplify ER α signaling in malignancy (Hanker et al., 2020). Further investigation is needed to clarify ER β 's physiological role and its impact on breast cancer progression (Kharb et al., 2020) (Wittmann et al., 2007).

This study aims to provide an overview of estrogen receptor signaling in breast cancer.

Materials And Methods

This study included 50 breast tissue specimens preserved in formalin and embedded in paraffin, all diagnosed histologically as invasive ductal carcinoma. The cohort comprised 22 male and 28 female patients. Samples were retrieved from the pathology archive of the Oncology Center in Wasit, following approval from the institutional ethics committee.

Tissue sections were prepared at a thickness of 4 μ m and stained with hematoxylin and eosin (H&E) to assess general histological architecture. For the evaluation of estrogen receptor alpha (ER α) expression, immunohistochemical (IHC) staining was performed using monoclonal anti-ER antibodies. The extent and intensity of nuclear staining were assessed using the Allred scoring system, which combines proportion and intensity scores to provide a semi-quantitative measure of receptor expression.

Results

Microscopic examination revealed typical features of invasive ductal carcinoma, including irregular glandular structures, nuclear pleomorphism, and increased mitotic activity. ER α expression was predominantly nuclear and varied in intensity across samples.

Male samples (n = 22), 44% showed moderate to strong ER α positivity. Female samples (n = 28) 56% demonstrated high ER α expression, with luminal A and B subtypes predominating (figures 1 & 2). The histological grade correlated with ER α expression, where lower-grade tumors exhibited stronger receptor positivity. Additionally, ER α -positive tumors showed reduced necrosis and better glandular differentiation.




Figure 1. Histological microphotographs of breast tissue from a 55-year-old female patient diagnosed with invasive ductal carcinoma, classified as estrogen receptor-positive luminal A subtype. (a) H&E staining reveals irregular glandular architecture, marked nuclear pleomorphism, and dense fibrous stroma. (b) IHC staining for ER α shows strong nuclear positivity (brown staining) in tumor cells, confirming ER-positive status consistent with luminal A classification.




Figure 2. Histological assessment of ER α expression in ER-positive breast cancer biopsies from male and female patients. (a) IHC staining of male breast cancer tissue ($n = 22$) shows moderate to strong nuclear ER α expression. (b) IHC staining of female breast cancer tissue ($n = 28$) reveals intense and uniform ER α nuclear positivity, consistent with luminal A and B subtypes.

Discussion

The histopathological evaluation confirmed hallmark features of invasive ductal carcinoma, including architectural distortion, nuclear pleomorphism, and elevated mitotic activity. These findings are consistent with the aggressive nature of this subtype and reinforce its predominance in breast cancer diagnoses (Garrido-Castro *et al.*, 2019).

Immunohistochemical analysis revealed that estrogen receptor alpha (ER α) expression was primarily nuclear and varied between male and female patients. Notably, 56% of female samples exhibited high ER α positivity, predominantly within luminal A and B subtypes, while 44% of male samples showed moderate to strong expression. This sex-based variation in ER α intensity may reflect underlying biological differences in tumor behavior and hormone responsiveness (Slepicka *et al.*, 2019).

The observed correlation between histological grade and ER α expression—where lower-grade tumors demonstrated stronger receptor positivity—supports the established notion that ER α -positive tumors tend to be more differentiated and less aggressive (Łukasiewicz *et al.*, 2021). Additionally, the reduced necrosis and improved glandular organization in ER α -positive cases further suggest a more favorable prognosis. (Prat *et al.*, 2013)

Figures 1 and 2 visually reinforce these findings, highlighting the contrast in ER α staining patterns and architectural features between male and female tissues. The intense and uniform nuclear staining in female

luminal tumors aligns with their classification and potential responsiveness to hormone therapy. (Garrido-Castro et al., 2019)

Importantly, these results underscore the clinical relevance of ER α as both a diagnostic marker and a therapeutic target. The differential expression across sexes and tumor grades may influence treatment planning, particularly in selecting candidates for endocrine therapy (Prat et al., 2015). Moreover, the presence of ER α in male breast cancer—though less frequent—warrants further investigation into tailored hormonal strategies for this subgroup (Winters et al., 2017). Overall, the data support the utility of ER α immunohistochemistry in stratifying breast cancer cases and guiding personalized treatment approaches (Godet & Gilkes, 2017).

Conclusions

This study highlights the central role of estrogen receptor (ER) signaling—both genomic and non-genomic—in the development, progression, and therapeutic targeting of breast cancer. The identification of ER isoforms and mutations, along with their contribution to endocrine resistance, underscores the complexity of hormone-dependent tumors. Advances in molecular profiling and targeted therapies, including SERMs, SERDs, CDK4/6 inhibitors, and epigenetic modulators, offer promising strategies to overcome resistance and improve patient outcomes. Continued research into ER biology and its variants remains essential for optimizing personalized treatment approaches.

Funding

None

Acknowledgement

The author acknowledges the Department of Biology, College of Education for Pure Sciences, University of Wasit, for academic support.

Conflicts Of Interest

The authors declare no conflict of interest.

References:

- Ciarloni, L., Mallepell, S., & Briskin, C. (2007). Amphiregulin is an essential mediator of estrogen receptor function in mammary gland development. *Proceedings of the National Academy of Sciences of the United States of America*, 104(13), 5455–5460.
- Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019). Insights into molecular classifications of triple-negative breast cancer. *Cancer Discovery*, 9(2), 176–198.
- Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019). Insights into molecular classifications of triple-negative breast cancer. *Cancer Discovery*, 9(2), 176–198.
- Godet, I., & Gilkes, D. M. (2017). BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. *Integrative Cancer Science and Therapeutics*, 4.

- Harbeck, N., Penault-Llorca, F., Cortes, J., et al. (2019). Breast cancer. *Nature Reviews Disease Primers*, 5, 66.
- Liang, Y., Zhang, H., Song, X., & Yang, Q. (2020). Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. *Seminars in Cancer Biology*, 60, 14–27.
- Łukasiewicz, S., Czezelewski, M., Forma, A., et al. (2021). Breast cancer- Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. *Cancers*, 13, 4287.
- Pandya, S., & Moore, R. G. (2011). Breast development and anatomy. *Clinical Obstetrics and Gynecology*, 54(1), 91–95.
- Pellacani, D., Tan, S., Lefort, S., & Eaves, C. J. (2019). Transcriptional regulation of normal human mammary cell heterogeneity and its perturbation in breast cancer. *The EMBO Journal*, 38(14), e100330.
- Prat, A., Cheang, M. C. U., Martín, M., et al. (2013). Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. *Journal of Clinical Oncology*, 31(2), 203–209.
- Prat, A., Pineda, E., Adamo, B., et al. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. *The Breast*, 24(Suppl 2), S26–S35.
- Rodriguez-Boulán, E., & Macara, I. G. (2014). Organization and execution of the epithelial polarity programme. *Nature Reviews Molecular Cell Biology*, 15(4), 225–242.
- Shiau, A. K., Barstad, D., Loria, P. M., et al. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism by tamoxifen. *Cell*, 95(7), 927–937.
- Slepicka, P. F., Cyrill, S. L., & dos Santos, C. O. (2019). Pregnancy and breast cancer: Pathways to understand risk and prevention. *Trends in Molecular Medicine*, 25(10), 866–881.
- Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249.
- Troyer, K. L., & Lee, D. C. (2001). Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. *Journal of Mammary Gland Biology and Neoplasia*, 6(1), 7–21.
- Winters, S., Martin, C., Murphy, D., & Shokar, N. K. (2017). Breast cancer epidemiology, prevention, and screening. *Progress in Molecular Biology and Translational Science*, 151, 1–32.
- Mal, R., Magner, A., David, J., et al. (2020). Estrogen receptor beta (ERβ): A ligand activated tumor suppressor. *Frontiers in Oncology*, 10, 587386.
- Girault, I., Lerebours, F., Amarir, S., et al. (2003). Expression analysis of estrogen receptor alpha coregulators in breast carcinoma. *Clinical Cancer Research*, 9(4), 1259–1266.
- Le Romancer, M., Poulard, C., Cohen, P., et al. (2011). Cracking the estrogen receptor's posttranslational code in breast tumors. *Endocrine Reviews*, 32(5), 597–622.
- Acconcia, F., Ascenzi, P., Bocedi, A., et al. (2005). Palmitoylation-dependent estrogen receptor alpha membrane localization. *Molecular Biology of the Cell*, 16(1), 231–237.
- Barton, M., Filardo, E. J., Lolait, S. J., et al. (2018). Twenty years of the G protein-coupled estrogen receptor GPER. *Journal of Steroid Biochemistry and Molecular Biology*, 176, 4–15.

- De Francesco, E. M., Pellegrino, M., Santolla, M. F., et al. (2014). GPER mediates activation of HIF1 α /VEGF signaling by estrogens. *Cancer Research*, 74(15), 4053–4064.
- Dustin, D., Gu, G., & Fuqua, S. A. W. (2019). ESR1 mutations in breast cancer. *Cancer*, 125(21), 3714–3728.
- Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020). Overcoming endocrine resistance in breast cancer. *Cancer Cell*, 37(4), 496–513.
- Kharb, R., Haider, K., Neha, K., & Yar, M. S. (2020). Aromatase inhibitors: Role in postmenopausal breast cancer. *Archiv der Pharmazie*, 353, 2000081.
- Wittmann, B. M., Sherk, A., & McDonnell, D. P. (2007). Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. *Cancer Research*, 67(19), 9549–9560.